Plastic surgery consolidation used to be something that happened in other specialties. Dermatology, ophthalmology and dental went first. Now private equity-backed groups are building plastic surgery platforms across the country, and surgeons who never expected to think about “the market” are being asked to pick a side.
This guide looks at the evidence, the five trends shaping consolidation in 2026, what could slow it down and what it means for an independent surgeon, whether you plan to sell, partner or stay on your own. It supports our main guide to putting a plastic surgery practice for sale.
Key takeaways
- Physician Growth Partners counts ten or more PE-backed plastic surgery platforms, six formed in a single 24-month period (PGP).
- FOCUS Investment Banking reported a 440% increase in plastic surgery deal volume over the two years to 2024 (FOCUS).
- Most practices are still independent, so consolidation has a long way to run.
- Tighter state rules on corporate control, like California’s SB 351, are changing how deals are structured.
What is plastic surgery consolidation?
Plastic surgery consolidation is the combining of independent practices into larger groups, mostly through private equity-backed platforms that acquire practices through management services organizations. It also includes physician-owned groups, mergers between practices and dermatology or aesthetics platforms adding surgeons. The result is fewer, larger owners in a market that used to be almost entirely independent.
The pace is new, but the pattern isn’t. The typical private equity cycle is for early platforms to grow by acquisition, then sell to larger investors who keep buying. Plastic surgery looks to be in the early-to-middle stage of that cycle.
How far has plastic surgery consolidation gone?
Further than a few years ago, but not far by the standards of other specialties. Physician Growth Partners lists ten or more PE-backed platforms and says most plastic surgeons remained independent as of 2023. FOCUS reported deal volume up 440% over the two years to 2024. The market is consolidating quickly from a low base.
Some of the platforms Physician Growth Partners names:
| Platform | Sponsor | Noted by PGP |
| Ascend Plastic Surgery Partners | Sheridan Capital | October 2023 |
| Athenix | Latticework Capital Management | Active platform |
| Inspire Aesthetics | Hidden Harbor Capital Partners | Active platform |
| Olympus Cosmetic Group | VSS | Active platform |
| United Aesthetics Alliance | Varsity Healthcare Partners | Named in PGP’s 2024 white paper |
| Advanced Reconstructive Surgery Alliance | Webster Equity Partners | Active platform |
| Cosmetic Physician Partners | Physician-owned MSO | No traditional PE sponsor |
Source: Physician Growth Partners. Sponsors and structures change over time, so confirm details before relying on them.
What can other specialties tell us?
They show where consolidation can lead. Dermatology, gastroenterology and ophthalmology have seen significant private equity activity, according to the Milbank Memorial Fund. A 2025 JAMA Ophthalmology study found about one in six ophthalmologists it studied were affiliated with private equity by 2020. Plastic surgery is earlier on that path.
The JAMA Ophthalmology study counted 3,129 PE-affiliated ophthalmologists out of 18,672 studied between 2016 and 2020. The Milbank Memorial Fund reports non-hospital corporate entities now employ or affiliate with more physicians than hospitals do, at 30.1% versus 28.4%. These are analogues, not forecasts, but they show the direction of travel across physician specialties.
5 plastic surgery consolidation trends for 2026
1. More platforms competing for practices
Physician Growth Partners noted six new platforms in a 24-month period, leaving more than twice as many groups looking to consolidate as before. More buyers means more competition for well-run practices.
2. Early platforms approaching their exit window
FOCUS describes a five-to-seven-year hold period in physician practice deals, and PitchBook reported that more than 30% of US PE-backed companies had been held at least five years by the end of 2024. Platforms formed in the early 2020s are approaching the point where sponsors look to sell.
3. Growth in non-surgical and aesthetics services
Platforms want recurring revenue from injectables and skin care alongside surgery. FOCUS cites ancillary revenue streams among the drivers of premium valuations, and dermatology and aesthetics groups are adding surgical capability.
4. Tighter state rules on corporate control
California’s SB 351 took effect January 1, 2026, restricting what private equity-backed managers can control in physician practices (Sidley Austin). Vermont’s Act 133 followed on July 1, 2026. Deals are being structured more carefully as a result.
5. Strong patient demand
The American Society of Plastic Surgeons reported cosmetic surgical procedures up 7% in 2025, led by lift procedures, with patients 66 and older up 24%. Growing demand supports buyer interest.
Why is plastic surgery consolidating now?
Because the economics favor scale and investors have capital to deploy. Marketing, technology, compliance and recruiting cost more every year, and larger groups can spread those costs. At the same time, cash-pay demand is growing and most practices are small and independent, which is exactly what a buy-and-build investor looks for.
Surgeon demographics add pressure. The AAMC reports that 23.9% of active physicians were 65 or older in 2024. Many surgeon-owners approaching retirement don’t have an internal successor, and a platform offers a way out that didn’t exist a decade ago.
What could slow plastic surgery consolidation?
State regulation, higher borrowing costs, a pullback in elective cosmetic spending and limits on physician non-competes could all slow it, or change how deals are structured. None seems likely to stop consolidation outright, but each can affect prices and terms, and some may push buyers toward physician-friendly structures.
In more detail:
- Regulation. California, Vermont and Oregon have tightened rules, and DLA Piper reports increased corporate practice enforcement in 2026 (DLA Piper).
- Financing costs. Acquisitions rely on debt. Higher rates make them more expensive.
- Consumer demand. Cosmetic surgery is discretionary, so a downturn can slow volumes.
- Non-compete limits. Many states now restrict physician non-competes, which affects how buyers protect goodwill.
What does plastic surgery consolidation mean for independent surgeons?
More options and more competition. Consolidation creates buyers for your practice, partners for growth and alternatives to a traditional associate buy-in. It also means competing against larger groups for patients, staff and marketing attention. Independent surgeons can thrive, but it helps to decide deliberately rather than by default.
Your realistic paths:
| Path | Best for | Watch out for |
| Sell to a platform | Surgeons wanting liquidity and support | Rollover risk, reduced independence |
| Join a physician-owned group | Surgeons wanting scale with physician control | Less capital, shared decisions |
| Stay independent | Surgeons with a strong brand and local density | Rising costs without scale |
| Build your own group | Surgeons with capital and management depth | Integration and recruiting risk |
Whatever you choose, know what your practice is worth. Our guide to who buys plastic surgery practices explains each buyer type, and our guide to private equity plastic surgery practices covers how PE deals work.
How does consolidation change practice values?
More buyers competing for good practices tends to support prices, especially for larger groups. FOCUS Investment Banking reported 2026 platform deals ranging from 5x to 6x EBITDA for smaller practices up to 9x to 12x or more for the largest, with add-ons at 5x to 9x. Where you land depends on size, surgeon depth and growth.
Consolidation also rewards scale directly. FOCUS describes $3 million of EBITDA as the point where multiples can rise by two to four turns, which is why some independents grow by merging with neighbors before they sell. Our guide to plastic surgery practice EBITDA multiples explains the numbers.
What role do physician-owned groups play?
A growing one. Some surgeons want the purchasing power, marketing and back-office support of a larger group without handing control to a private equity sponsor. Physician-owned MSOs and multi-surgeon groups offer that middle path. Physician Growth Partners lists Cosmetic Physician Partners as one physician-owned MSO without a traditional PE sponsor.
These groups usually pay less upfront than private equity platforms, because they have less capital. In return, surgeons keep more say in decisions and avoid a sponsor’s exit timeline. For surgeons who value independence but feel the pressure of rising costs, they’re worth including in any comparison.
How does plastic surgery consolidation affect patients and staff?
For patients, the visible effects are often small at first: the same surgeon, the same office, sometimes new branding or booking systems. For staff, larger groups may bring better benefits and training, along with centralized billing, marketing and administration that can change roles. The effects depend heavily on how each buyer operates.
That’s why surgeons who sell should ask detailed questions about staff pay, benefits and roles, and about how clinical decisions and marketing claims are governed after the sale. Research on private equity in other specialties is mixed, so the specific buyer’s track record matters more than general claims either way.
What should independent surgeons do in the next 12 months?
Get a current valuation, track the metrics buyers use, reduce dependence on yourself, and decide what you’d want if a strong offer arrived. None of this commits you to selling. It simply means that when plastic surgery consolidation reaches your market, you’ll be making choices from a position of knowledge.
A short action list:
- Get an independent recast of your earnings and a value range.
- Start or advance an associate search.
- Build monthly reporting on consultations, conversions and revenue by service.
- Review your contracts, leases and facility accreditation.
- Learn which platforms are active in your region, and how they’ve treated surgeons who joined.
How can independent practices compete?
Build a strong local brand, invest in patient experience and online reputation, add associate surgeons and injectors, track the metrics that matter and control costs. Well-run independent practices remain attractive to patients and, if you ever change your mind, to buyers too.
Good management is the common thread. The same habits that help you compete with larger groups also make your practice more valuable. Our guide to plastic surgery practice management covers the metrics buyers and successful independents both track.
Frequently asked questions
Is plastic surgery consolidating?
Yes. Physician Growth Partners counts ten or more PE-backed plastic surgery platforms, with six formed in a single 24-month period. FOCUS Investment Banking reported a 440% increase in plastic surgery deal volume over the two years to 2024. Most practices remain independent, so consolidation has room to continue.
Who is consolidating the plastic surgery industry?
Mainly private equity-backed platforms such as Athenix, Inspire Aesthetics, Ascend Plastic Surgery Partners and Olympus Cosmetic Group, according to Physician Growth Partners. Physician-owned groups like Cosmetic Physician Partners, and dermatology and aesthetics platforms adding surgeons, are also part of the trend.
Will plastic surgery follow dermatology and ophthalmology?
It may follow a similar path, though not necessarily to the same degree. Those specialties have seen significant private equity activity, and a 2025 JAMA Ophthalmology study found about one in six ophthalmologists it studied were PE-affiliated by 2020. Plastic surgery is earlier in the cycle, and new state rules may shape it differently.
What could slow down plastic surgery consolidation?
Tighter state rules on corporate control, higher borrowing costs, weaker consumer spending on elective procedures and limits on physician non-competes. California’s SB 351 and Vermont’s Act 133, both effective in 2026, are examples of regulation that is changing how buyers structure deals.
Should independent plastic surgeons worry about consolidation?
Not worry, but plan. Consolidation creates buyers and partners as well as competitors. Independent surgeons with strong brands, good management and local density can thrive. The key is knowing your practice’s value and your options, so you can respond to offers or competition deliberately.
Can I stay independent in a consolidating market?
Yes. Many surgeons will. Strong patient relationships, a trusted local brand, solid management and an associate surgeon help independent practices compete. Staying independent works best as a deliberate choice, backed by regular valuations, so you can judge any offer against real numbers.
Plastic surgery consolidation: the bottom line
Plastic surgery consolidation is accelerating from a low base, driven by growing demand, cash-pay economics and private equity capital, and shaped by tougher state rules. For independent surgeons, it means more choices. Understand the market, know your value and choose your path on purpose.
| Wondering how consolidation affects your practice? Get the Plastic Surgery Exit Report newsletter for quarterly market updates, or book a confidential conversation with the plastic surgery team at Olympic M&A. Disclosure: Plastic Surgery Exit Report is published in partnership with Olympic M&A, a healthcare M&A advisory firm. |
